News | April 02, 2024
Apotex to acquire Canadian Searchlight Pharma
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The company had earlier announced about the approval received from the MHRA for Liraglutide
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Subscribe To Our Newsletter & Stay Updated
